| P2093 | author name string | Paul E Drawz | |
| | Scott Reule | |
| | Boutros El-Haddad | |
| P2860 | cites work | Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease | Q79226809 |
| | Glomerular hyperfiltration in type 1 diabetes mellitus results from primary changes in proximal tubular sodium handling without changes in volume expansion | Q81697684 |
| | Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms | Q24299673 |
| | Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy | Q24657470 |
| | Cardiorenal end points in a trial of aliskiren for type 2 diabetes | Q28278569 |
| | Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats | Q28565932 |
| | Global estimates of the prevalence of diabetes for 2010 and 2030 | Q29547218 |
| | US Renal Data System 2012 Annual Data Report | Q30582337 |
| | Angiotensin II type 1 receptor overexpression in podocytes induces glomerulosclerosis in transgenic rats | Q31063566 |
| | Telmisartan, ramipril, or both in patients at high risk for vascular events | Q33156143 |
| | Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence | Q34321390 |
| | Sodium zirconium cyclosilicate in hyperkalemia | Q34448992 |
| | A systematic review of the role of renin angiotensin aldosterone system genes in diabetes mellitus, diabetic retinopathy and diabetic neuropathy | Q35025285 |
| | Tubular epithelial-myofibroblast transdifferentiation mechanisms in proximal tubule cells | Q35032352 |
| | Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway | Q36598311 |
| | Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). | Q37087865 |
| | Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study | Q37368689 |
| | Renin-angiotensin-aldosterone system blockade for nephroprotection: current evidence and future directions | Q38017616 |
| | Current concepts of renal hemodynamics in diabetes | Q40952838 |
| | Renal tubular hypertrophy induced by angiotensin II. | Q41605129 |
| | Combination of direct renin inhibition with angiotensin type 1 receptor blockade improves aldosterone but does not improve kidney injury in the transgenic Ren2 rat. | Q42154496 |
| | Additive hypotensive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rats | Q43607543 |
| | Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus | Q44242766 |
| | Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats | Q44390510 |
| | Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy | Q44390528 |
| | Plasma aldosterone concentration in the patient with diabetes mellitus | Q44845998 |
| | Effect of angiotensin II on glomerular structure in streptozotocin-induced diabetic rats | Q45148071 |
| | Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats | Q45396552 |
| | Combined angiotensin inhibition for the treatment of diabetic nephropathy | Q46129784 |
| | Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 |
| | Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension | Q46660460 |
| | Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells | Q46681426 |
| | Activation of a local renin angiotensin system in podocytes by glucose | Q46794009 |
| | Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats | Q47298474 |
| | Declining Incidence of Nephropathy in Insulin-Dependent Diabetes Mellitus | Q57449606 |
| | Improved prognosis of diabetic nephropathy in type 1 diabetes | Q61948356 |
| | Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? | Q67858660 |
| | Mortality of workers in two Minnesota taconite mining and milling operations | Q69832138 |
| | Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications | Q69890202 |
| | Early diabetes mellitus stimulates proximal tubule renin mRNA expression in the rat | Q73293199 |
| | Angiotensin II type 1-receptor mediated changes in heparan sulfate proteoglycans in human SV40 transformed podocytes | Q75205967 |
| | Angiotensin III up-regulates genes involved in kidney damage in mesangial cells and renal interstitial fibroblasts | Q77635349 |
| P433 | issue | 10 | |
| P304 | page(s) | 70 | |
| P577 | publication date | 2015-10-01 | |
| P1433 | published in | Current diabetes report | Q26841965 |
| P1476 | title | Dual Renin-Angiotensin-Aldosterone System Inhibition for the Treatment of Diabetic Kidney Disease: Adverse Effects and Unfulfilled Promise | |
| P478 | volume | 15 | |